AM Report: Stocks Edge Higher Ignoring Grim Round Of Economic Readings

By Tom Piotrowski | More Articles by Tom Piotrowski

US sharemarkets were mixed on Thursday. Restraining prices was a disappointment on a trial of a COVID-19 vaccine. The Financial Times said Gilead Science’s Remdesivir did not improve patients’ conditions in a Chinese trial.